The U.S. Food and Drug Administration rejected ImClone 's original application in December 2001 , saying the trial had been sloppily conducted .
The Food and Drug Administration rejected ImClone 's 2001 application to sell Erbitux , citing shoddy research .
Two federal agencies are looking into telecommunications gear maker Lucent Technologies for potencial U.S. bribe constitutional cracks in its operations in Saudi Arabia.